The significance of sFas and sFasL expression on neoadjuvant chemotherapy of breast cancer
10.3969/j.issn.1005-1678.2016.12.053
- VernacularTitle:sFas和sFasL在乳腺癌新辅助化疗过程中的表达及意义
- Author:
Yang SONG
;
Yanping HU
;
Rui WANG
- Keywords:
fatty acid synthase ligand;
soluble fatty acid synthase receptor;
breast cancer;
neoadjuvant chemotherapy
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(12):183-185
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the expression and significance of fatty acid synthase ligand ( sFas ) and soluble fatty acid synthase receptor (sFasL) on the neoadjuvant chemotherapy of breast cancer.Methods 84 cases of patients with breast cancer neoadjuvant chemotherapy were recorded from January 2015 to January 2016 in our hospital as breast cancer group,another 84 cases of healthy subjects as control group,the two groups were measured sFas,the positive rate of sFasL.At the same time,respectively before and after neoadjuvant chemotherapy, detection of patients serum sFas, sFasL levels and breast cancer.According to the clinical curative effect were divided into effective group and ineffective group , compared two groups of serum sFas, sFasL levels.Results Breast cancer group called sFas and sFasL positive rate was 58.33% (49/84) and 100.00%(84/84),were significantly higher than that of control group 38.10%(32/84) and 0.00% (0/84);The level of sFas in patients with neoadjuvant chemotherapy was significantly lower than that of neoadjuvant chemotherapy, and the level of sFas in neoadjuvant chemotherapy group was significantly higher than that in ineffective group, the difference was statistically significant (P<0.05).Conclusion In the course of neoadjuvant chemotherapy for breast cancer,the efficacy of neoadjuvant chemotherapy can be effectively detected by detecting the level of serum sFas in patients with breast cancer , while sFasL has no significant change in the neoadjuvant chemotherapy of breast cancer.
